Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions.

Elstner M, Müller SK, Leidolt L, Laub C, Krieg L, Schlaudraff F, Liss B, Morris C, Turnbull DM, Masliah E, Prokisch H, Klopstock T, Bender A.

Mol Brain. 2011 Dec 21;4:43. doi: 10.1186/1756-6606-4-43.

2.

Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.

Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL.

Prog Neurobiol. 2005 Feb;75(2):109-24. Review.

PMID:
15784302
3.

Modifications of the iron-neuromelanin system in Parkinson's disease.

Fasano M, Bergamasco B, Lopiano L.

J Neurochem. 2006 Feb;96(4):909-16. Epub 2006 Jan 17. Review.

4.

Detrimental deletions: mitochondria, aging and Parkinson's disease.

Biskup S, Moore DJ.

Bioessays. 2006 Oct;28(10):963-7. Review.

PMID:
16998822
5.

Neuronal vulnerability in Parkinson's disease.

Double KL.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S52-4. doi: 10.1016/S1353-8020(11)70018-9. Review.

PMID:
22166454
6.

Neuromelanin of the human substantia nigra: an update.

Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, Zecca L.

Neurotox Res. 2014 Jan;25(1):13-23. doi: 10.1007/s12640-013-9435-y. Epub 2013 Oct 24. Review.

PMID:
24155156
7.

Neuronal vulnerability, pathogenesis, and Parkinson's disease.

Sulzer D, Surmeier DJ.

Mov Disord. 2013 Jun;28(6):715-24. doi: 10.1002/mds.25187. Epub 2013 Apr 15. Review.

PMID:
23589357
8.
9.

7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.

Lehéricy S, Bardinet E, Poupon C, Vidailhet M, François C.

Mov Disord. 2014 Nov;29(13):1574-81. doi: 10.1002/mds.26043. Epub 2014 Oct 12. Review.

PMID:
25308960
10.

Dopaminergic and noradrenergic circuit development in zebrafish.

Schweitzer J, Lohr H, Filippi A, Driever W.

Dev Neurobiol. 2012 Mar;72(3):256-68. doi: 10.1002/dneu.20911. Review.

11.

Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.

Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P.

Neurotox Res. 2003;5(1-2):35-44. Review.

PMID:
12832223
12.

The enigma of neuromelanin in Parkinson's disease substantia nigra.

Youdim MB, Ben-Shachar D, Riederer P.

J Neural Transm Suppl. 1994;43:113-22. Review.

PMID:
7884393
13.

[Catecholaminergic neurons of mammalian brain and neuromelanin].

Sukhorukova EG, Alekseeva OS, Korzhevskii DE.

Zh Evol Biokhim Fiziol. 2014 Sep-Oct;50(5):336-42. Review. Russian.

PMID:
25786315
14.

The human substantia nigra and ventral tegmental area. A neuroanatomical study with notes on aging and aging diseases.

van Domburg PH, ten Donkelaar HJ.

Adv Anat Embryol Cell Biol. 1991;121:1-132. Review.

PMID:
2053466
15.
16.

Neuronal vulnerability, pathogenesis, and Parkinson's disease.

Sulzer D, Surmeier DJ.

Mov Disord. 2013 Jan;28(1):41-50. doi: 10.1002/mds.25095. Epub 2012 Jul 12. Review.

17.

New face of neuromelanin.

Double KL, Halliday GM.

J Neural Transm Suppl. 2006;(70):119-23. Review.

PMID:
17017518
18.

The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Mazzio EA, Close F, Soliman KF.

Int J Mol Sci. 2011 Jan 17;12(1):506-69. doi: 10.3390/ijms12010506. Review.

19.

Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.

Hatano T, Okuzumi A, Kamagata K, Daida K, Taniguchi D, Hori M, Yoshino H, Aoki S, Hattori N.

J Neural Transm (Vienna). 2017 Apr;124(4):407-415. doi: 10.1007/s00702-017-1688-9. Epub 2017 Feb 3. Review.

PMID:
28160151
20.

Organotypic brain slice cultures: A review.

Humpel C.

Neuroscience. 2015 Oct 1;305:86-98. doi: 10.1016/j.neuroscience.2015.07.086. Epub 2015 Aug 5. Review.

Supplemental Content

Support Center